Navigation Links
Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia
Date:6/13/2008

Compound Inhibits Mutant Forms of BCR-ABL That Cause Resistance to Current

CML and ALL Therapies

COPENHAGEN, Denmark, June 13 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today reported preliminary phase 1 data from an ongoing trial of XL228 in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ALL) who are resistant to or intolerant of the approved BCR-ABL inhibitors imatinib and dasatinib. XL228 is a small molecule inhibitor of BCR-ABL, SRC, and insulin-like growth factor type 1 receptor (IGF1R), which are associated with cancer cell proliferation, survival, and metastasis. The compound also potently inhibits the T315I mutant form of BCR-ABL, which is resistant to all currently approved inhibitors. Dr. Jorge Cortes, Professor of Medicine, Deputy Chair, Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, and an investigator on the phase 1 trial, presented the data in a poster session (Abstract #1260) at the 13th Congress of the European Hematology Association.

Seventeen subjects have received at least one dose of XL228, of whom 16 had completed Cycle 1 as of May 15, 2008. The trial is evaluating a treatment cycle consisting of 4 weekly 1-hour IV infusions of XL228 at doses ranging from 0.45 mg/kg to 7.2 mg/kg. Thirteen of the 17 subjects (76.5%) have BCR-ABL mutations, including seven (41.2%) with the T315I mutation. At the 3.6 and 7.2 mg/kg doses (either as part of Cohorts 4 and 5 or through dose escalation from a previous cohort), all subjects have demonstrated stable or decreasing white blood cell counts. A CML patient with an F317L BCR-ABL mutation in lymphoid blast crisis experienced
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO
2. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
3. Exelixis Announces First Quarter 2008 Financial Results
4. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
5. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
6. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
7. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
8. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
9. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
10. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
11. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Fla. , Dec. 19, 2014 Breckenridge ... a multi-product agreement with MSN Laboratories Pvt. Ltd. ( ... MSN expect to commercialize several new ANDAs.  Under the ... supply the products exclusively to Breckenridge for the U.S. ... under its label.  Breckenridge and MSN have agreed to ...
(Date:12/19/2014)... , Dec. 19, 2014  Monarch America Inc. (OTCQB: ... Corp.) is pleased to provide this review of the ... in 2015. "Over this past year, we ... I am extremely proud to say that Monarch America ... than it has ever been," stated Eric Hagen ...
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research ... announced the addition of the "Micro Market ... report to their offering. ... dermatological treatment is progressing steadily, which has resulted ... diagnostic devices market. The main purpose of these ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3
... 2007 - Geron,Corporation (Nasdaq:GERN) today announced the ... company's human,embryonic stem cell (hESC)-based therapeutic for ... direct attack by the human immune,system., Presented ... Federation of,Clinical Immunology Societies meeting in San ...
... BETHESDA, Md., June 11, 2007--New research supported ... of Arthritis and,Musculoskeletal and Skin Diseases (NIAMS) ... which is used for certain,types of seizures, ... pain and,other symptoms associated with the common, ...
Cached Medicine Technology:Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 2Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 3Gabapentin Shown Effective for Fibromyalgia Pain 2Gabapentin Shown Effective for Fibromyalgia Pain 3
(Date:12/21/2014)... 21, 2014 Over the past 39 ... in hundreds of emergency departments across the nation, from ... have been translated into an innovative suite of tools, ... deficiencies and enhance the patient experience. , NES ... staffing and management services for hospitals, announced the development ...
(Date:12/21/2014)... Vancouver, WA (PRWEB) December 21, 2014 CannabisClassifieds.com ... website redesign. The only one of its kind, the ... to find local marijuana for 14 years running. It ... Angie’s List to make cannabis readily available to the masses. ... way to grasping the golden ring of public approval. ...
(Date:12/20/2014)... BambooIndustry.com is a leading eco-friendly ... announced its bamboo flooring promotion for the coming ... certified suppliers, and offers the best bamboo products ... current promotion, all customers can enjoy a special ... they know BambooIndustry.com from press releases. , The ...
(Date:12/20/2014)... Dress company LunaDress has recently announced its ... Sale, offering big discounts on all of its special occasion ... to own a perfect wedding gown. If you have no ... come to LunaDress. Many different wedding dress styles and our ... now and enjoy the current special offer, up to 80% ...
(Date:12/20/2014)... Recently, VogueQueen.com, a leading wedding dress wholesaler and retailer, ... for 2015. Great discounts are now offered on all ... get a discount, up to 80% off, when they ... 30, 2015. , VogueQueen.com has recently released its new ... promotion. Many customers worldwide like VogueQueen’s special designs which ...
Breaking Medicine News(10 mins):Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:VogueQueen Big Sale Online For The Coming 2015 2
... America,s Health (TFAH) and the Partnership for Prevention ... vs. Sick Care. , "This ad campaign conveys how ... care system from a sick care system to one that ... of TFAH. "The evidence is clear that prevention is the ...
... 28 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA ... commercialization of clinical-stage product candidates for central nervous system ... quarter ended September 30, 2009, on Monday, November 2, ... of the release will be disseminated at that time. ...
... announced results for the third quarter ended September 30, 2009. Financial highlights from continuing operations for the third quarter of 2009 ... (amounts in millions, except per share amounts), ... ... ...
... NASDAQ: CRME TSX: COM, ... Pharma Corp. (NASDAQ: CRME/TSX: COM) and its co-development partner Astellas ... begun for the ACT 5 trial, a confirmatory Phase 3 ... candidate under development for the rapid conversion of atrial fibrillation ...
... Modest reduction may be worthwhile for those most at ... News) -- Children who are predisposed to recurrent urinary ... a new Australian study suggests that such prophylactic therapy ... Only 13 percent of youngsters who were given the ...
... ... new state-of-the-art digital radiology laboratory, Spencer Peller of 123Chiropractors.com presents the donation check to ... , ... NY (PRWEB) November 3, 2009 -- 123Chiropractors.com, http://www.123chiropractors.com , the world,s largest portal ...
Cached Medicine News:Health News:New Health Care vs. Sick Care Ad Campaign Launched by Trust for America's Health and Partnership for Prevention 2Health News:New Health Care vs. Sick Care Ad Campaign Launched by Trust for America's Health and Partnership for Prevention 3Health News:Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009 2Health News:Carriage Services Announces Third Quarter 2009 Results 2Health News:Carriage Services Announces Third Quarter 2009 Results 3Health News:Carriage Services Announces Third Quarter 2009 Results 4Health News:Carriage Services Announces Third Quarter 2009 Results 5Health News:Carriage Services Announces Third Quarter 2009 Results 6Health News:Carriage Services Announces Third Quarter 2009 Results 7Health News:Carriage Services Announces Third Quarter 2009 Results 8Health News:Carriage Services Announces Third Quarter 2009 Results 9Health News:Carriage Services Announces Third Quarter 2009 Results 10Health News:Carriage Services Announces Third Quarter 2009 Results 11Health News:Carriage Services Announces Third Quarter 2009 Results 12Health News:Carriage Services Announces Third Quarter 2009 Results 13Health News:Carriage Services Announces Third Quarter 2009 Results 14Health News:Carriage Services Announces Third Quarter 2009 Results 15Health News:Carriage Services Announces Third Quarter 2009 Results 16Health News:Carriage Services Announces Third Quarter 2009 Results 17Health News:Carriage Services Announces Third Quarter 2009 Results 18Health News:Carriage Services Announces Third Quarter 2009 Results 19Health News:Carriage Services Announces Third Quarter 2009 Results 20Health News:Cardiome And Astellas Announce Initiation Of Patient Enrolment In ACT 5 Trial 2Health News:Cardiome And Astellas Announce Initiation Of Patient Enrolment In ACT 5 Trial 3Health News:Cardiome And Astellas Announce Initiation Of Patient Enrolment In ACT 5 Trial 4Health News:Preventive Antibiotics Help Some Kids Fend Off Urinary Infections 2Health News:Preventive Antibiotics Help Some Kids Fend Off Urinary Infections 3Health News:World's Largest Resource for and about Chiropractors, 123Chiropractors.com, Donates $15,000 to Life Chiropractic College West 2Health News:World's Largest Resource for and about Chiropractors, 123Chiropractors.com, Donates $15,000 to Life Chiropractic College West 3
Inquire...
... incubators,Two refrigerated incubators that are ... life cycle,testing. Microprocessor controlled heating ... display. High/low audible and visual ... internal chamber safety thermostat,provides over-temperature ...
Inquire...
Inquire...
Medicine Products: